A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis.
The intestinal anti-inflammatory effects of two probiotics isolated from breast milk, Lactobacillus reuteri and L. fermentum, were evaluated and compared in the trinitrobenzenesulfonic acid (TNBS) model of rat colitis. Colitis was induced in rats by intracolonic administration of 10 mg TNBS dissolved in 50% ethanol (0.25 ml). Either L. reuteri or L. fermentum was daily administered orally (5 x 10(8) colony-forming units suspended in 0.5 ml skimmed milk) to each group of rats (n 10) for 3 weeks, starting 2 weeks before colitis induction. Colonic damage was evaluated histologically and biochemically, and the colonic luminal contents were used for bacterial studies and for SCFA production. Both probiotics showed intestinal anti-inflammatory effects in this model of experimental colitis, as evidenced histologically and by a significant reduction of colonic myeloperoxidase activity (P<0.05). L. fermentum significantly counteracted the colonic glutathione depletion induced by the inflammatory process. In addition, both probiotics lowered colonic TNFalpha levels (P<0.01) and inducible NO synthase expression when compared with non-treated rats; however, the decrease in colonic cyclo-oxygenase-2 expression was only achieved with L.fermentum administration. Finally, the two probiotics induced the growth of Lactobacilli species in comparison with control colitic rats, but the production of SCFA in colonic contents was only increased when L. fermentum was given. In conclusion, L. fermentum can exert beneficial immunomodulatory properties in inflammatory bowel disease, being more effective than L. reuteri, a probiotic with reputed efficacy in promoting beneficial effects on human health.
Peran
Laura
L
Department of Pharmacology, University of Granada, Universitario La Cartuja, Spain.
Sierra
Saleta
S
Comalada
Mònica
M
Lara-Villoslada
Federico
F
Bailón
Elvira
E
Nieto
Ana
A
Concha
Angel
A
Olivares
Mónica
M
Zarzuelo
Antonio
A
Xaus
Jordi
J
Gálvez
Julio
J
D000818:Animals; D003092:Colitis / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D003106:Colon / Q000276:immunology / Q000382:microbiology; D003967:Diarrhea / Q000276:immunology / Q000473:pathology / Q000628:therapy; D005232:Fatty Acids, Volatile / Q000032:analysis / Q000096:biosynthesis; D005243:Feces / Q000382:microbiology; D005260:Female; D005766:Gastrointestinal Contents / Q000737:chemistry / Q000382:microbiology; D005978:Glutathione / Q000032:analysis / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D015212:Inflammatory Bowel Diseases; D007413:Intestinal Mucosa / Q000276:immunology / Q000378:metabolism; D052197:Limosilactobacillus fermentum; D052200:Limosilactobacillus reuteri; D023421:Models, Animal; D018482:Muscle, Skeletal; D009929:Organ Size; D009195:Peroxidase / Q000032:analysis / Q000378:metabolism; D019936:Probiotics; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen; D013950:Thymus Gland; D014302:Trinitrobenzenesulfonic Acid; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000378:metabolism
D005232:Fatty Acids, Volatile; D014409:Tumor Necrosis Factor-alpha; D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase; D005978:Glutathione